We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Loss of Brain White Matter Increases Stroke Risk

By Biotechdaily staff writers
Posted on 31 Jul 2003
Researchers have established that leukoaraiosis, changes in the brain's white matter that usually occur in the elderly, increases the risk of multiple strokes.

Investigators studied 685 patients aged 34 to 84 years with carotid artery disease who participated in the 2,885-patient North American Symptomatic Carotid Endarterectomy Trial (NASCET) and who had a follow-up computed tomography (CT) scan taken three years or more from entry in the study.

Of the 685 patients in the study, 596 had no leukoaraiosis and 89 had limited white matter. More...
During an average follow-up of 6.1 years, 18% of the 596 patients initially free of leukoaraiosis developed some loss of white matter and 3% had widespread loss. The average age of patients who developed leukoaraiosis was 66.8 years.

The group of patients who developed leukoaraiosis showed a higher tendency to experience at least one stroke: 36% versus 23.5% for the group without leukoaraiosis. After taking gender, age, smoking history, and diseases such as hypertension and diabetes mellitus into consideration, results showed that the patients who developed leukoaraiosis were 1.5 times more likely to have a stroke. The findings were published July 17, 2003, in the online edition of Stroke.

"Patients who developed leukoaraiosis were more likely to have multiple strokes, which generally lead to increased disability, both physically and mentally,” said first author Dr. Jonathan Y. Streifler, director of the neurology unit at the Rabin Medical Center (Petach Tikva, Israel). "These small strokes can be devastating when they hit strategic connections.”

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.